GlassScriptPhysician profile
Aleksandr Orlovskiy
NPI 1457501447
$5,272.52
in general payments reported to CMS, 2019-2025
38 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $160 · 2021: $989 · 2022: $1,428 · 2023: $835 · 2024: $874 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,584.52 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.16 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $472.46 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $312.85 | 2019-2025 | Trelegy Ellipta |
| Ardelyx, INC. | $183.37 | 2024-2025 | Ibsrela |
| Amgen INC. | $177.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $161.71 | 2019-2025 | |
| Medtronic, INC. | $154.57 | 2023-2025 | Cg Future, Percept PC Brainsense |
| Cumberland Pharmaceuticals, INC. | $143.28 | 2022 | |
| Lilly USA, LLC | $132.13 | 2020-2023 | Mounjaro |
| Ironwood Pharmaceuticals, INC | $130.40 | 2021-2024 | Linzess |
| Amarin Pharma, INC. | $125.86 | 2019-2022 | |
| Genzyme Corporation | $119.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $104.09 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $103.16 | 2024-2025 | Vowst |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Orlovskiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.